Literature DB >> 3589692

High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia.

M A Sanz, J Martínez, D Borrego, G Martín-Aragonés, I Lorenzo, G Sanz, M J Sayas, I Jarque, E Pastor, J Rafecas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3589692

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  3 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  High-dose ara-C and etoposide in refractory or relapsing acute leukemia.

Authors:  M Freund; H Link; H Diedrich; S LeBlanc; H J Wilke; H Poliwoda
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.

Authors:  M Freund; S Giller; F Hinrichs; A Baars; J Meran; A Körfer; H Link; H Poliwoda
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.